Zealthy vs iV.im: Biomarker & Genetics GLP-1

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Zealthy and iV.im have emerged as competing telehealth platforms in the GLP-1 space, each offering distinct screening frameworks and provider networks. Zealthy focuses on rapid assessment with limited biomarker depth, while iV.im emphasizes more comprehensive health profiling before prescribing GLP-1 medications, according to their published service models.

Choosing between Zealthy versus iV.im requires understanding how each platform evaluates your candidacy—and what biomarker or genetic insights each recommends. PlexusDx takes a different precision-wellness approach: compounded GLP-1 options paired with optional Precision Peptide Genetic Testing, allowing you to explore genetic pathways in GLP-1 receptors and metabolic genes before committing to any medication.

Zealthy's Telehealth Model and Biomarker Approach

Zealthy operates as a direct-to-consumer platform with a streamlined, asynchronous assessment process. Members complete a questionnaire and connect with licensed providers remotely; the platform prioritizes accessibility and speed over extensive lab work, making it popular among cost-conscious seekers.

Biomarker screening on Zealthy is minimal—typically limited to blood pressure, weight, and BMI intake data. The platform does not mandate fasting labs or genetic testing, focusing instead on clinical eligibility criteria such as BMI thresholds and medical history flags. This approach suits candidates already confident in their GLP-1 readiness.

iV.im's Health Profiling and Biomarker Integration

iV.im positions itself as a full-spectrum telehealth provider, requiring more granular health data before GLP-1 prescribing. The platform collects extensive questionnaire responses, encourages baseline lab work (lipid panel, glucose, liver and kidney function), and may recommend metabolic biomarker review in advance.

This comprehensive intake mirrors traditional clinical practice and appeals to members with complex medical histories or those seeking integrated wellness monitoring. iV.im does not currently offer genetic pathway testing but uses biomarker data to tailor provider discussions and dosing recommendations.

Biomarker Framework: Zealthy vs iV.im Side-by-Side

Both platforms serve GLP-1 candidates but differ significantly in their clinical depth and data collection philosophy. The table below contrasts their screening approaches, helping you identify which aligns with your health profile and preference for personalized assessment.

Assessment Factor	Zealthy	iV.im
Primary Health Screening	Questionnaire only; minimal biomarkers	Questionnaire + optional baseline labs
Fasting Labs (glucose, lipids, liver/kidney)	Not required; optional at member request	Encouraged; integrated into initial assessment
Genetic Pathway Testing	Not offered	Not offered
Provider Network Type	Licensed MDs/NPs via asynchronous platform	Licensed providers with integrated health coaching
Typical Assessment Timeline	24–48 hours	3–7 days (includes lab review)
Cost Structure	Monthly membership + medication costs	Tiered membership + labs (if external) + meds

Genetic Readiness: Where Zealthy and iV.im Fall Short

Neither Zealthy nor iV.im currently integrates genetic pathway testing into their GLP-1 candidacy assessment. Both rely on clinical phenotype (age, BMI, comorbidities) and biomarker snapshots, but neither explores individual variation in GLP1R, GIPR, FTO, or MC4R genes that may influence response patterns.

Genetic insights in peptide metabolism can inform provider conversations about expected tolerance, dose titration, and likelihood of metabolic benefit. Without this layer, both platforms use a one-size-fits-many approach rather than true precision medicine. PlexusDx's Precision Peptide Genetic Test fills this gap—designed to reveal predispositions in these four key GLP-1 pathway variants.

Which Platform Fits Your Clinical Profile?

If you have stable metabolic health and minimal medication interactions, Zealthy's streamlined model may suffice. You'll reach a provider quickly and begin GLP-1 therapy without extensive testing, assuming you meet basic BMI and age criteria. Ideal for lower-risk, younger, or already-healthy candidates.

If you have diabetes, hypertension, fatty liver disease, or take multiple medications, iV.im's biomarker-informed approach offers more thorough pre-prescription review. The platform's emphasis on baseline labs and provider integration reduces guesswork about your metabolic baseline, supporting safer dose titration and monitoring during therapy.

Safety Considerations and Medical Eligibility

Both Zealthy and iV.im screen for absolute contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and active pancreatitis. Both require honest disclosure of medication allergies, cardiovascular history, and kidney function. Incomplete or inaccurate reporting on either platform increases adverse-event risk.

GLP-1 medications carry real side effects—nausea, dehydration, gallbladder complications, and potential pancreatitis. Platform choice does not eliminate these risks; it only changes the depth of pre-prescription assessment. Medical supervision, even asynchronous, is essential. Neither platform replaces in-person care for complex cases, and both should escalate to local emergency care if serious symptoms emerge.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that both Zealthy and iV.im serve real patient needs, but neither integrates genetic pathway insights into their assessment framework. Genetic variation in GLP1R, GIPR, FTO, and MC4R genes may influence individual response to GLP-1 therapy—including side-effect tolerance, dose optimization, and metabolic benefit. This genetic context is not predictive of exact outcomes but may help provide context for provider conversations about personalized expectations.

The PlexusDx Precision Peptide Genetic Test is designed to reveal predispositions in these four key GLP-1 pathway variants. It is available as a standalone assessment ($298) or as an add-on ($99) when paired with compounded GLP-1 options from our licensed 503A compounding partners. The test can support a more informed discussion with any provider—whether on Zealthy, iV.im, or elsewhere—about your genetic readiness for GLP-1 therapy.

Consider genetic testing if you are exploring GLP-1 candidacy, have experienced medication sensitivities in the past, or want to optimize your provider conversation before starting therapy. Results should be interpreted with a qualified healthcare provider, not as a standalone decision tool. PlexusDx compounded semaglutide and tirzepatide options allow you to pursue GLP-1 therapy at lower price points than many telehealth platforms, freeing budget for additional personalization tools like genetic pathway testing.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the key difference between Zealthy and iV.im?

Zealthy prioritizes speed and low friction, requiring minimal biomarker data before GLP-1 eligibility. iV.im emphasizes comprehensive health profiling, encouraging baseline labs and more detailed provider review. Zealthy suits lower-risk candidates; iV.im serves those with complex medical histories.

Does Zealthy or iV.im offer genetic testing for GLP-1 readiness?

Neither platform currently integrates genetic pathway testing into their assessment. PlexusDx offers optional Precision Peptide Genetic Testing to reveal predispositions in GLP1R, GIPR, FTO, and MC4R variants, supporting more personalized provider conversations regardless of which platform you choose.

Which platform is cheaper overall?

Zealthy typically costs $99–$199 monthly plus medication; iV.im ranges $150–$250 monthly plus meds and lab costs. PlexusDx compounded semaglutide starts at $179/month and tirzepatide at $229/month—often lower than both platforms' total combined costs.

Can I use genetic testing results with Zealthy or iV.im?

Yes. Genetic insights can inform conversations with any provider, including those on Zealthy or iV.im. Share results with your assigned provider to support discussions about expected tolerance, dose titration, and metabolic outcomes, though neither platform currently interprets genetic pathway data in their assessment.

How do I decide between Zealthy, iV.im, and PlexusDx compounded options?

Consider your medical complexity: Zealthy for rapid, minimal-screening access; iV.im for comprehensive biomarker review; PlexusDx for lower-cost compounded therapy plus optional genetic insights. None guarantee outcomes—all require honest health disclosure and provider supervision.

Is PlexusDx compounded semaglutide the same as branded Ozempic or Wegovy?

No. PlexusDx offers compounded semaglutide from licensed 503A pharmacies, which differs from branded Ozempic (insulin treatment) or Wegovy (GLP-1 marketed for weight). Compounded versions are not FDA-approved as branded drugs but are legal, regulated pharmacy compounds prepared under state and federal oversight.

Zealthy vs iV.im: Biomarker Screening and Genetic Readiness for GLP-1